Research and Development Investment: Opthea Limited vs Geron Corporation

Biotech R&D: Opthea vs Geron - A Decade of Growth

__timestampGeron CorporationOpthea Limited
Wednesday, January 1, 2014207070003401685
Thursday, January 1, 2015178310004284228
Friday, January 1, 2016180470003581295
Sunday, January 1, 2017110330004838300
Monday, January 1, 20181343200024891534
Tuesday, January 1, 20195207200031347891
Wednesday, January 1, 20205148800017480747
Friday, January 1, 20218572700034710152
Saturday, January 1, 202295518000108459978
Sunday, January 1, 2023125046000181563523
Monday, January 1, 2024176326321
Loading chart...

Igniting the spark of knowledge

A Decade of Innovation: Opthea Limited vs Geron Corporation

In the ever-evolving landscape of biotechnology, research and development (R&D) investments are pivotal. Over the past decade, Opthea Limited and Geron Corporation have demonstrated contrasting strategies in their R&D expenditures. From 2014 to 2023, Opthea Limited's R&D spending surged by an impressive 5,200%, peaking in 2023. In contrast, Geron Corporation's investment grew by approximately 500% over the same period, with a notable spike in 2023.

Key Insights

  • Opthea Limited: The company showed a consistent upward trend, with a significant leap in 2022, marking a 210% increase from the previous year.
  • Geron Corporation: Despite a slower growth rate, Geron maintained steady investments, culminating in a 31% increase in 2023.

These trends highlight the dynamic nature of R&D investments in the biotech sector, reflecting each company's strategic focus and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025